For many years now, the retina subspecialty has been no stranger to innovation. Rather than providing a detailed narrative of the long list of developments that include pharmacotherapy, genetics, surgical techniques and equipment, drug delivery, and imaging, we think it's fair to simply state that this has been and continues to be an exciting time to be a retina specialist.

In this issue of Retina Today, which features our annual cover focus on innovation in retina, we have a variety of topics representing the wide range of developments that have recently taken place. Although it would be impossible to cover everything, we planned this issue so that we could provide readers with important updates as well as hopefully provide new insight into some developments that are on the horizon.

Julia A. Haller, MD, was interviewed for this issue regarding the recent studies that were published in the New England Journal of Medicine on ocriplasmin for the treatment of vitreomacular adhesion. We chose this conversational format because you've most likely read articles or seen data presented on this topic in the past. Dr. Haller provides frank insight as to what the availability of ocriplasmin might mean to your own practice.

We have also included an article by Alexander M. Eaton, MD, on a new device that was recently unveiled at recent retina congresses that could possibly improve upon the safety of intravitreal injections.

On the imaging front, Paul Hahn, MD, and Cynthia Toth, MD, provide an update on their work with intraoperative optical coherence tomography. Further, Michael A. Singer, MD; Colin S. Tan, MBBS, FRCSEd (Ophth), MMed (Ophth); and SriniVas R. Sadda, MD, discuss peripheral imaging of the retina in the setting of rebound edema in retinal vein occlusion and describe how this can be helpful in maximizing treatment efforts.

Alan Franklin, MD, PhD, provides an excellent overview of genetic studies that were presented at the Association for Research in Vision and Ophthalmology meeting this past May, and discusses how new genetic tests can help clinicians provide earlier treatment for their patients with agerelated macular degeneration.

Regarding treatments currently in development, David S. Boyer, MD, has assisted us with a review of the data for integrin peptide therapy, which represents an entirely different class of treatment for patients with AMD and DME. David Bar-Or, MD; Gregory Thomas, BS; Kristin Salottolo, MPH; Alessandro Orlando, MPH; and Vaughan Clift, MD, present very new information on an oral treatment for DME. Finally, Timothy L. Jackson, PhD, FRCOphth, summarizes the recent data from the Euretina meeting on stereotactic radiotherapy.

We hope you enjoy our innovations issue. Feel free to contact us with any suggestions for topics you would like us to cover in future issues.